I Mab Stock Investor Sentiment

IMAB Stock  USD 0.93  0.02  2.11%   
About 62% of I Mab's investor base is looking to short. The analysis of overall sentiment of trading I Mab stock suggests that many investors are alarmed at this time. The current market sentiment, together with I Mab's historical and current headlines, can help investors time the market. In addition, many technical investors use I Mab stock news signals to limit their universe of possible portfolio assets.
  
over a year ago at kalkinemedia.com         
I-Mab and ABL Bio Announce Latest Updates of PD-L1 and 4-1BB Bispecific Antibody TJ-L14BABL503
news
over a year ago at finance.yahoo.com         
I-Mab and ABL Bio Announce Latest Updates of PD-L1 and 4-1BB Bispecific Antibody TJ-L14BABL503
Yahoo News
over a year ago at hawaiinewsnow.com         
I-Mab and ABL Bio Announce Latest Updates of PD-L1 and 4-1BB Bispecific Antibody TJ-L14BABL503
news
over a year ago at news.google.com         
Kyowa acquiring gene therapy firm Orchard for up to 478M - BioWorld Online
Google News at Macroaxis
over a year ago at news.google.com         
Form 424B5 KINETA, INC.DE - StreetInsider.com
Google News at Macroaxis
over a year ago at thelincolnianonline.com         
I-Mab Short Interest Update
news
over a year ago at news.google.com         
The week in pharma action, reaction and insight week to ... - The Pharma Letter
Google News at Macroaxis
over a year ago at news.google.com         
Mitchells Butlers Has Some Way To Go To Become A Multi-Bagger - Yahoo Finance
Google News at Macroaxis
over a year ago at news.google.com         
Anticancer monoclonal antibodies Market Size and Overview Analysis 2023 by Industry Dynamics, Emergi...
Google News at Macroaxis
over a year ago at thelincolnianonline.com         
I-Mab PT Lowered to 23.00
news
over a year ago at news.google.com         
AbbVie terminates deal with I-Mab to develop cancer drug - Nasdaq
Google News at Macroaxis
over a year ago at reuters.com         
AbbVie terminates deal with I-Mab to develop cancer drug
reuters
over a year ago at news.google.com         
Inmagene announces formation of Celexor Bio based on its anti-ILT7 mAb with enhanced pDC depletion f...
Google News at Macroaxis
over a year ago at news.google.com         
NBIO Follow Up.. More Signs of Deep Value as Stock Takes Flight - Nascent Biotech - Benzinga
Google News at Macroaxis
over a year ago at news.google.com         
I-Mab Why This Company Trades At A Third The Value Of Its Cash ... - Seeking Alpha
Google News at Macroaxis
Far too much social signal, news, headlines, and media speculation about I Mab that are available to investors today. That information is available publicly through IMAB media outlets and privately through word of mouth or via IMAB internal channels. However, regardless of the origin, that massive amount of IMAB data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of I Mab news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of I Mab relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to I Mab's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive I Mab alpha.

I Mab Performance against Dow Jones

 Price Growth (%)  
       Timeline  

Complementary Tools for IMAB Stock analysis

When running I Mab's price analysis, check to measure I Mab's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy I Mab is operating at the current time. Most of I Mab's value examination focuses on studying past and present price action to predict the probability of I Mab's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move I Mab's price. Additionally, you may evaluate how the addition of I Mab to your portfolios can decrease your overall portfolio volatility.
Sectors
List of equity sectors categorizing publicly traded companies based on their primary business activities
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Money Managers
Screen money managers from public funds and ETFs managed around the world